Clinical Trial Update: Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of Dynavax's CpG 1018 adjuvant (1018 ISS) used after Rituxan in patients with B-cell follicular lymphoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• 1018 ISS (CpG 1018 oligodeoxynucleotide adjuvant)
• Rituxan (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED